复方藤梨汤联合化疗治疗结直肠癌术后临床研究
DOI:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R735.34

基金项目:


Clinical Study on Compound Tengli Tang Combined with Chemotherapy for Patients After Colorectal Cancer Surgery
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察复方藤梨汤联合化疗治疗结直肠癌术后的临床疗效。方法:选择结直肠癌术后患者80 例,依据治疗方法不同分为对照组和观察组各40 例。对照组术后4~6 周开始采用FOLFOX6 方案化疗,观察组在对照组基础上给予复方藤梨汤口服。比较2 组治疗前后中医证候积分、血常规、肿瘤标志物、体力状况、免疫功能及炎症因子水平,评价2 组临床疗效及不良反应发生情况、复发转移情况及1 年、2 年生存情况。结果:观察组总缓解率为90.0%,高于对照组60.0%,差异有统计学意义(P<0.05)。治疗后,2 组中医证候积分、血小板(BPC)、红细胞计数(RBC)、白细胞计数(WBC)、癌胚抗原(CEA)、糖类抗原199 (CA199)、糖类抗原724 (CA724) 水平较治疗前降低(P<0.05);且观察组中医证候积分、癌胚抗原(CEA)、糖类抗原199(CA199)、糖类抗原724(CA724) 水平低于对照组,BPC、RBC、WBC 均高于对照组(P<0.05)。2 组Karnofsky 功能状态评分(KPS) 较治疗前升高,且观察组KPS 评分高于对照组(P<0.05)。治疗后,2 组CD4+较治疗前升高,且观察组CD4+高于对照组(P<0.05)。观察组恶心呕吐、食欲减退、口周麻痹、腹胀腹泻发生率、复发转移率均低于对照组(P<0.05),1 年、2 年生存率均高于对照组(P< 0.05)。结论:复方藤梨汤联合化疗治疗结直肠癌术后患者较单独化疗效果更好,可以提高患者免疫功能,改善临床症状,减少不良反应发生率及复发率。

    Abstract:

    Abstract: Objective: To observe the clinical effect of compound Tengli tang combined with chemotherapy for patients after colorectal cancer surgery. Methods:A total of 80 cases of patients who had undergone colorectal cancer surgery were selected and divided into the control group and the observation group according to different treatment methods, with 40 cases in each group. The control group was treated with chemotherapy with FOLFOX6 scheme in four to six weeks after the surgery, and the observation group was additionally given the oral administration of compound Tengli tang based on the treatment of the control group. Chinese medicine syndrome scores, blood routine, tumor markers, physical status,immune function,and inflammatory factor levels were compared between the two groups before and after treatment. Clinical effects, incidence of adverse reactions, recurrence and metastasis status,and one-year and two-year survival status in the two groups were evaluated. Results:The total remission rate was 90.0% in the observation group,higher than that of 60.0% in the control group,the difference being significant(P<0.05). After treatment,Chinese medicine syndrome scores,and the levels of blood platelet count(BPC),red blood cell count(RBC),white blood cell count(WBC),carcinoembryonic antigen(CEA),carbohydrate antigen 199(CA199),and carbohydrate antigen 724(CA724) in the two groups were decreased when compared with those before treatment(P<0.05); Chinese medicine syndrome scores, and levels of CEA, CA199, and CA724 in the observation group were lower than those in the control group,and levels of BPC,RBC and WBC were higher(P<0.05). Scores of Karnofsky Performance Status(KPS) in the two groups were increased when compared with those before treatment,and the score in the observation group was higher than that in the control group(P<0.05). After treatment,levels of CD4+ in the two groups were increased when compared with those before treatment,and CD4+ in the observation group was higher than that in the control group(P<0.05). The recurrence and metastasis rates as well as the incidence of nausea and vomiting, decreased appetite, perioral paralysis, and abdominal distension and diarrhea in the observation group were lower than those in the control group(P<0.05),and the one- year and two- year survival rates were higher(P<0.05). Conclusion: For patients after colorectal cancer surgery, compound Tengli tang combined with chemotherapy has a better effect than that of simple chemotherapy. It can enhance immune function, improve clinical symptoms and reduce the incidence of adverse reactions and recurrence rates.

    参考文献
    相似文献
    引证文献
引用本文

王艳,吴进.复方藤梨汤联合化疗治疗结直肠癌术后临床研究[J].新中医,2022,54(15):139-143

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2022-08-04
  • 出版日期: